Shanghai Kehua Bio-Engineering Co., Ltd. (hereinafter referred to as KHB, Stock code: 002022.SZ) is founded in 1981. It was the 1^st publically listed IVD Company in China. Over the last 41 years, KHB has a full-line diagnostic products of immune diagnosis, Clinical Chemistry diagnosis, molecular diagnosis and POCT, and developed into a high-tech company that integrates R&D, manufacturing and business.

Headquartered in Shanghai, KHB has set up R&D centers and production bases in Italy and China. Currently, the company has over 2,000 employees. Being a hi-tech enterprise certified by Shanghai, KHB has established postdoctoral research station, Shanghai Research Center for Immune Diagnostic Engineering and Shanghai Innovation Center for Clinical IVD Reagents.

With its mission of "Caring for life, dedicate to excellence", vision of “To become a leading company on a global stage” and its values of “customer first, innovation, collaboration, responsibility, and pragmatism, driven by innovation and lean management, KHB focuses on in vitro diagnostics and is committed to welfare of human beings.